• Diane Zisa and Susan M Goodman.
• Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA.
• Med. Clin. North Am. 2021 Mar 1; 105 (2): 273-284.

AbstractPatients with rheumatic disease, including those with systemic lupus erythematous, rheumatoid arthritis, and spondyloarthritis, use total hip and knee arthroplasties at high rates. They represent a particularly vulnerable population in the perioperative setting because of their diseases and the immunosuppressant therapies used to treat them. Careful planning among internists, medical specialists, and the surgical team must therefore occur preoperatively to minimize risks in the postoperative period, particularly infection. Management of immunosuppressant medications, such as conventional synthetic disease-modifying antirheumatic drugs and targeted therapies including biologics, is one avenue by which this infectious risk can be mitigated.Copyright © 2020 Elsevier Inc. All rights reserved.

14 keywords...

hide…